June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Induction of experimental keratoconic ectasias by Endo-β-Galactosidase extracellular matrix digestion
Author Affiliations & Notes
  • Federico Bech
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
  • Ignacio Alcalde
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
  • Almudena Íñigo-Portugués
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
  • Paola Braga
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
  • Enol Artime
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
  • Beatriz Garcia
    Departamento de Biología Funcional, Universidad de Oviedo, Oviedo, Spain
  • Jose Alfonso
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
    Departamento de Oftalmología, Universidad de Oviedo, Oviedo, Spain
  • Jesus Merayo-Lloves
    Superficie Ocular, Fundación de Investigación Oftalmológica, Oviedo, Spain
    Departamento de Oftalmología, Universidad de Oviedo, Oviedo, Spain
  • Footnotes
    Commercial Relationships Federico Bech, None; Ignacio Alcalde, None; Almudena Íñigo-Portugués, None; Paola Braga, None; Enol Artime, None; Beatriz Garcia, None; Jose Alfonso, None; Jesus Merayo-Lloves, Ferrara & Hijos SL (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2998. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Federico Bech, Ignacio Alcalde, Almudena Íñigo-Portugués, Paola Braga, Enol Artime, Beatriz Garcia, Jose Alfonso, Jesus Merayo-Lloves; Induction of experimental keratoconic ectasias by Endo-β-Galactosidase extracellular matrix digestion. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2998.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The keratoconus disease has been related with structural defects due to the overexpression of keratocan, which can alter the fibrillogenesis in the stroma. The development of pharmacological approaches to keratoconus reveals the need of reproducible experimental models. The aim of this work is to generate a mouse model of keratoconus by degradation of the proteoglycan extracellular matrix suitable to test drug or cell based therapies.

Methods: To induce a keratoconic ectasia in mice, corneas were thinned using photorefractive keratectomy (PRK). Once the epithelium was removed mice were treated with the enzyme Endo-β-Galactosidase for 5 days at two concentrations (50 mU and 100 mU). After 10 days, the eye globes were characterized by optical keratometry, hematoxylin-eosin staining and by immunohistochemistry techniques to demonstrate Keratocan, TrkA, β-Catenin and MMP9. Therapeutic treatments with adipose mesenchymal stem cells (AMSC) and Plasma Rich in Growth Factors (PRGF) were tested. AMSC were isolated from human lipoaspirates and cultured with a defined medium before dropped it directly onto the eye surface for 5 days. Other group was treated paralelly with PRGF.

Results: Keratometric analysis reveals that 40% of the corneas treated with Endo-β-Galactosidase at 100 mU develop a cone shape fifteen days after the PRK. The hematoxylin-eosin staining reveal an epithelial and stromal thinning at the site of the keratoconic ectasia. Moreover, a relative increase ot the expression of Keratocan and β-Catenin was observed in conic corneas. Otherwise, the TrkA and MMP9 expression was virtually nil in ectasic corneas. Treatment with stem cells showed the integration of AMSC into the stroma and an increase of corneal thickness. Both AMSC and PRGF produced a partial restoration of the ectasia.

Conclusions: Treatment with Endo-β-Galactosidase and PRK produce a reproducible mouse model that shares morphological and molecular features with human keratoconus This model is a good platform to test new biological strategies to treat keratoconus.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×